Young H, Baum R, Cremerius U; et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Journal of Cancer. 1999, 35 (13): 1773–1782. 引文格式1维护:显式使用等标签 (link)
Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, and Langstrom B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Annals of Neurology. 2004, 55 (3): 306–319.
Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, Lavretsky H, Burggren AC, Cole GM, Vinters HV, Thompson PM, Huang SC, Satyamurthy N, Phelps ME, and Barrio JR. PET of brain amyloid and tau in mild cognitive impairment. New England Journal of Medicine. 2006, 355 (25): 2652–2663.
Positron Emission Particle Tracking (页面存档备份,存于互联网档案馆) (PEPT)—engineering analysis tool based on PET that is able to track single particles in 3D within mixing systems or fluidised beds. Developed at the University of Birmingham, UK.